Setback for Bristol-Myers on Lung Cancer Treatment Drugs
Bristol-Myers Squibb suffers a setback in immunotherapy treatment for newly diagnosed lung cancer.
A setback for Bristol-Myers Squibb (BMY) - Get Report as the company says it will not seek accelerated approval for a combination of two drugs -- Opdivo and Yervoy -- as a treatment for newly diagnosed lung cancer. Bristol didn't provide details about its decision other than to say its reviewing data at this time. It's now looking like the approval filing won't occur until early next year, assuming the study results are positive. The delay gives competitor Merck (MRK) - Get Report a significant head start in the lung cancer immunotherapy market.
